Stocky turns companies like 10x Genomics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. TXG scores poorly across growth (35/100) and value (36/100) metrics, indicating weak earnings power and limited expansion prospects. Leadership alignment is middling (61/100), and the company faces a vulnerable financial position with only a thin buffer against downturns—a critical flaw for a low-growth business.
How safely 10x Genomics, Inc. is financed, graded A++ (strongest) to C from the last five years of accounts: debt against earnings, interest cover, cash against debt, how high and steady profit margins are, return on capital, and whether it generated cash every year. Not part of the Stocky score.
Every stock is scored across six dimensions built to answer one question — can this business keep compounding? — without a Bloomberg subscription. Here's the actual snapshot for 10x Genomics, Inc.:
Quality + moat + leadership + valuation fused into a single 0–100 number. When you see 38/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
We don't claim a backtest. The top-scoring basket is recorded every month and measured against the S&P 500 from that date onward — judged on what it said before the outcome was known. The record is young, and published as it stands.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates 10x Genomics, Inc. (TXG) at 38/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation into a single number. Avoid. TXG scores poorly across growth (35/100) and value (36/100) metrics, indicating weak earnings power and limited expansion prospects. Leadership alignment is middling (61/100), and the company faces a vulnerable financial position wit
TXG's current Stocky Verdict is 38/100, placing it in the "Avoid" band. This composite combines a 36/100 Compounder score, 61/100 Leadership, 23/100 Moat rating.
10x Genomics, Inc. rates Limited moat (23/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
10x Genomics, Inc. scores 61/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
10x Genomics, Inc.'s Resilience Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to 10x Genomics, Inc..
Sign up free and unlock the full analysis on TXG — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TXG in the app.
